glp-1 based therapeutics summit 3rd GLP-1-Based 2026 [04/14/26] 2nd GLP-1-Based Therapeutics Summit |

IV therapy becomes the right call when you cannot keep fluids down, show warning signs of significant dehydration, or cannot absorb oral treatment due to illness

Monitoring and measuring results Rogan's experience with peptides includes the crucial element of paying attention to results

At week 72, the clinical data showed that 36.8% of patients receiving semaglutide achieved fibrosis improvement without worsening of NASH and 62.9% achieved NASH resolution without worsening of fibrosis, compared with 22.4% and 34.3%, respectively, in the placebo group (Sanyal et al., 2025)

- Duration: Use until desired tanning is achieved, then maintenance dosing as needed (e.g., 1 mg per week)

At the same time, gross spending increased ninefold, from about $1 billion in 2019 to almost $9 billion in 2024, and gross spending per GLP-1 prescription reached $1,000 in 2024

CagriSema , combining semaglutide with cagrilintide (an amylin analog), represents another approach